Selective blockade of classical-pathway activation downstream of C1q will reduce synaptotoxic complement amplification while preserving beneficial C1q recognition functions
The debate revealed fundamental disagreement about whether C1q has spatially distinct functions at synapses versus microglia, or whether outcomes depend solely on binding partners. This mechanistic uncertainty undermines all proposed therapeutic strategies targeting C1q.
Source: Debate session sess_SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1 (Analysis: SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1)
The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway protease activity than on C1q recognition alone. In this model, inhibiting C1r/C1s should attenuate C4/C3-mediated synapse loss and neuroinflammation while preserving some homeostatic debris sensing and cargo recognition by C1q.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["C1Q Deficiency Impaired Clearance of Apoptotic Cells"]
B["C1QC Assembly Heterocomplex Formation"]
C["Synaptic Pruning Dysregulation Unpruned Connections"]
D["Microglial Overactivation Complement Deposition"]
E["C3b/C4b Deposition Neuronal Surface"]
F["Synaptic Loss Excessive Pruning in AD"]
G["Long-Term Potentiation Memory Formation Impaired"]
H["Cognitive Decline AD-Related Dementia"]
A --> B
B --> C
B --> D
C --> F
D --> E
E --> F
F --> G
G --> H
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for C1QA,C1QB,C1QC,C1R,C1S,C4A,C4B,C3 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
10 citations10 with PMID5 mediumValidation: 0%8 supporting / 2 opposing
✓For(8)
5
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Early AD-model synapse loss requires classical complement components and microglial CR3, supporting the idea t…▼
Early AD-model synapse loss requires classical complement components and microglial CR3, supporting the idea that downstream cascade activation mediates injury.
The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functio…MEDIUM▼
The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functions by modulating DRD1 signaling or directly binding to Abeta.
It remains unresolved whether C1q recognition is broadly beneficial in the CNS; some harmful effects may arise…▼
It remains unresolved whether C1q recognition is broadly beneficial in the CNS; some harmful effects may arise from C1q binding itself rather than only downstream protease activation.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Synaptic C1q drives complement-dependent pruning, while microglial surface-associated C1q biases phagocyte state through receptor-specific signaling
Mechanism: C1q deposited on weak or stressed synapses preferentially nucleates the classical complement cascade (`C1q -> C4 -> C3`), generating opsonins that engage microglial CR3/ITGAM-ITGB2 and promote engulfment. In contrast, C1q bound directly to microglial receptors or pericellular ligands may alter microglial transcriptional state without requiring full downstream complement activation. This would make localization mechanis
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Overall skeptical read: the debate is probably mixing three separable variables that have not been cleanly orthogonalized experimentally: `location`, `ligand identity`, and `receiver-cell state`. The strongest evidence supports synaptic C1q/C3/CR3-mediated pruning in development and AD models, but that does not by itself prove a distinct microglial surface-signaling program for C1q, nor a binding-partner hierarchy that dominates location. Much of the translational logic is still mouse-heavy and disease-model dependent. Key anchors: synaptic pruning by C1q/C3 in development ([PMID: 18083105](ht
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Triage
The ideas worth carrying forward are `6`, `5`, `1`, `2`, `4`, and `7`, in that order. I would drop `3` for now; it is too speculative to support a drug program.
The main translational point is that only one of these is close to a druggable thesis today: `block classical-pathway activation downstream of C1q` rather than trying to solve all C1q biology first. The rest are mostly mechanism, stratification, or endpoint-selection hypotheses.
Feasibility: Highest. This is the cleanest therapeutic hypothesis becaus
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Selective blockade of classical-pathway activation downstream of C1q will reduce synaptotoxic complement amplification while preserving beneficial C1q recognition functions","description":"The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway protease activity than on C1q recognition alone. In this model, inhibiting C1r/C1s should attenuate C4/C3-mediated synapse loss and neuroinflammation while preserving some homeostatic debris sensing and cargo recognition by C1q.","target_gene":"C1QA,C1QB,C1QC
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF a selective C1r/C1s inhibitor (e.g., C1s-IN-1, 10 mg/kg daily) is administered to APP/PS1 transgenic mice starting at 3 months of age for 8 weeks, THEN the density of excitatory synapses in the hippocampus (measured by PSD95 immunostaining) will be significantly higher (≥20% increase) compared to vehicle-treated mice.
pendingconf: 0.65
Expected outcome: Hippocampal PSD95+ synapse density will increase by at least 20% relative to vehicle control.
Falsified by: If PSD95+ synapse density in treated mice is not higher than vehicle (p>0.05) or is lower, the hypothesis is disproven.
Method: Randomized, vehicle-controlled study in APP/PS1 mice (n≥12 per group) with blinded quantification of synaptic markers after 8 weeks of treatment.
IF human iPSC-derived neurons co-cultured with microglia are treated with a selective C1r/C1s inhibitor (C1s-IN-1, 1 µM) for 48 h prior to exposure to oligomeric Aβ (1 µM), THEN the generation of C3a in the culture supernatant (measured by ELISA) will be reduced by at least 30% relative to vehicle, while C1q binding to synapses (assessed by immunofluorescence) remains unchanged.
pendingconf: 0.55
Expected outcome: Supernatant C3a concentration will be at least 30% lower in inhibitor-treated cultures, with no significant change in C1q synaptic coverage.
Falsified by: If C3a levels are not reduced (p>0.05) or if C1q synaptic binding is significantly altered, the hypothesis is disproven.
Method: In vitro assay using iPSC-derived neuron-microglia co-cultures (n≥4 replicates) with multiplex ELISA and confocal imaging after Aβ exposure.